Role of aldose reductase and arginase inhibitors in diabetic vascular and behavioral complications. | ||
| Zagazig Journal of Pharmaceutical Sciences | ||
| Article 5, Volume 23, Issue 1, 2014, Pages 58-72 PDF (300.65 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zjps.2014.38182 | ||
| Authors | ||
| Waleed Barakat1; Reham Hassan1; Mohamed Askar2; Ahmad Fahmy1 | ||
| 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. | ||
| 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt | ||
| Abstract | ||
| Diabetes mellitus is an endocrine disorder that is associated with several microvascular and macrovascular complications in addition to complications within the central nervous system (CNS). Diabetic encephalopathy secondary to chronic hyperglycemia is mediated through oxidative stress, increased advanced glycation end products (AGEs), and impairment in cerebral insulin signaling. The Aim of the work was to investigate whether inhibition of aldose reductase and arginase enzyme can protect against vascular and behavior complications. Diabetes was induced in male wistar rats by a single intraperitoneal injection of streptozotocin (STZ, 50 mg/kg). Eight weeks later, diabetic rats were orally treated with ferulic acid (20 mg/kg), cinnamaldehyde (20 mg/kg), norvalline (50 mg/kg), ornithine (200 mg/kg) and citrulline (50 mg/kg) every day for 8 weeks. Body weight, blood glucose, serum AGEs level, blood pressure and behavioral change in memory and cognition were investigated at the end of the study. Streptozotocin caused a state of hyperglycemia associated with both vascular and behavioral complications as evidenced by the elevation in blood pressure and reduction in the Y-maze score and elevation in the transfer latency in the elevated plus maze. Blockade of aldose reductase and arginase enzyme ameliorated some of these complications without exerting any hypoglycemic effect. These results suggest the possible effectiveness of aldose reductase and arginase inhibitors in the management of diabetic vascular and behavioral complications together with conventional antidiabetic therapy. | ||
| Keywords | ||
| diabetes; Complications; aldose reductase; arginase; inhibitors; protection | ||
|
Statistics Article View: 150 PDF Download: 274 |
||
